Clinical Trial Update: A Study of IMGN901 for Patients With Advanced Solid Tumors and Extensive Stage Small Cell Lung Cancer [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 clinical trial update for IMGN901 in advanced solid tumors and extensive stage small cell lung cancer; the study has terminated with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Small Cell Lung Cancer

Drugs mentioned

• IMGN901 (lorvotuzumab mertansine)

Snippet

Sponsor: ImmunoGen, Inc. | Conditions: Small Cell Lung Cancer | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2018-01-18